RU2019128062A - Вдыхаемые составы на основе никотина и способы их получения и применения - Google Patents

Вдыхаемые составы на основе никотина и способы их получения и применения Download PDF

Info

Publication number
RU2019128062A
RU2019128062A RU2019128062A RU2019128062A RU2019128062A RU 2019128062 A RU2019128062 A RU 2019128062A RU 2019128062 A RU2019128062 A RU 2019128062A RU 2019128062 A RU2019128062 A RU 2019128062A RU 2019128062 A RU2019128062 A RU 2019128062A
Authority
RU
Russia
Prior art keywords
composition
nicotine
amino acid
sugar
mint
Prior art date
Application number
RU2019128062A
Other languages
English (en)
Other versions
RU2770039C2 (ru
RU2019128062A3 (ru
Inventor
Алекс Стенцлер
Ноэ ЦАМЕЛЬ
Артур СЛУТСКИ
Стивен ЭЛЛИС
Стив Хэн
Original Assignee
Филип Моррис Продактс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/452,133 external-priority patent/US10149844B2/en
Application filed by Филип Моррис Продактс С.А. filed Critical Филип Моррис Продактс С.А.
Publication of RU2019128062A publication Critical patent/RU2019128062A/ru
Publication of RU2019128062A3 publication Critical patent/RU2019128062A3/ru
Application granted granted Critical
Publication of RU2770039C2 publication Critical patent/RU2770039C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (16)

1. Сухой порошкообразный состав на основе никотина, содержащий от 0,5% до 5% никотина, по меньшей мере один сахар и по меньшей мере одну аминокислоту, выбранную из группы, состоящей из глицина, лизина, лейцина и их комбинации, где состав является подходящим для вдыхания.
2. Состав по п. 1, дополнительно содержащий по меньшей мере один фосфолипид.
3. Состав по п. 1, где никотин представляет собой тартрат никотина.
4. Состав по п. 1, где концентрация сахара составляет от 50% до 99%.
5. Состав по п. 1, где концентрация аминокислоты составляет от 0,5% до 50%.
6. Состав по п. 1, дополнительно содержащий ментол.
7. Состав по п. 1, дополнительно содержащий мяту.
8. Сухой порошкообразный состав на основе никотина, состоящий из никотина, по меньшей мере одного сахара, мяты и по меньшей мере одной аминокислоты, выбранной из группы, состоящей из глицина, лизина и лейцина, где состав является подходящим для вдыхания.
9. Состав по п. 8, где размер частиц по меньшей мере приблизительно 40% никотина и аминокислоты составляет от 3 до 4 микрон.
10. Состав по п. 8, где размер частиц по меньшей мере приблизительно 80% никотина и аминокислоты составляет от 1 до 7 микрон.
11. Состав по п. 8, где размер частиц сахара составляет по меньшей мере приблизительно 50 микрон.
12. Состав по п. 8, где размер частиц мяты составляет по меньшей мере приблизительно 20 микрон.
13. Сухой порошкообразный состав на основе никотина, содержащий частицы никотина, содержащие от 0,5% до 10% никотина и от 50% до 99% по меньшей мере одного сахара, и частицы по меньшей мере одной аминокислоты, выбранной из группы, состоящей из глицина, лизина и лейцина, где частицы аминокислоты по сути не связаны с частицами никотина, и при этом состав является подходящим для вдыхания.
14. Состав по п. 13, дополнительно содержащий по меньшей мере один фосфолипид.
15. Состав по п. 13, дополнительно содержащий ментол.
16. Состав по п. 13, дополнительно содержащий мяту.
RU2019128062A 2017-03-07 2018-03-07 Вдыхаемые составы на основе никотина и способы их получения и применения RU2770039C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/452,133 US10149844B2 (en) 2015-09-16 2017-03-07 Inhalable nicotine formulations, and methods of making and using thereof
US15/452,133 2017-03-07
PCT/IB2018/051482 WO2018163085A1 (en) 2017-03-07 2018-03-07 Inhalable nicotine formulations, and methods of making and using thereof

Publications (3)

Publication Number Publication Date
RU2019128062A true RU2019128062A (ru) 2021-04-07
RU2019128062A3 RU2019128062A3 (ru) 2021-05-21
RU2770039C2 RU2770039C2 (ru) 2022-04-14

Family

ID=61731727

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019128062A RU2770039C2 (ru) 2017-03-07 2018-03-07 Вдыхаемые составы на основе никотина и способы их получения и применения

Country Status (9)

Country Link
EP (1) EP3592352A1 (ru)
JP (1) JP2020510002A (ru)
KR (1) KR20190126772A (ru)
CN (1) CN110300588A (ru)
CA (1) CA3048677A1 (ru)
IL (1) IL268458A (ru)
MX (1) MX2019010263A (ru)
RU (1) RU2770039C2 (ru)
WO (1) WO2018163085A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502582A (ja) * 2019-11-14 2023-01-25 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 改善されたたばこ風味付き乾燥粉末製剤
EP4208151B1 (en) * 2020-09-03 2024-07-10 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions
CN112841709B (zh) * 2021-01-20 2022-11-25 深圳市艾普生物科技有限公司 一种尼古丁盐的制备方法及应用
CN113880802A (zh) * 2021-11-09 2022-01-04 深圳萨特瓦生物科技有限公司 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法
WO2024091005A1 (ko) * 2022-10-27 2024-05-02 주식회사 케이티앤지 기침 억제제를 함유한 건조 분말 흡입기용 스틱 및 이를 포함한 건조 분말 흡입기
CN117322671A (zh) * 2023-11-01 2024-01-02 东莞市吉纯生物技术有限公司 一种烟碱脂质体及其制备方法与电子雾化液

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099428T3 (es) * 1992-03-10 1997-05-16 Fisons Plc Composiciones farmaceuticas para inhalacion.
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU8111301A (en) * 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
AU2002333644A1 (en) * 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US7832397B2 (en) * 2005-12-28 2010-11-16 Philip Morris Usa Inc. Aerosol powder delivery device
WO2008069972A2 (en) * 2006-12-01 2008-06-12 Aradigm Corporation Systems for effecting cessation of tobacco use
EP2739268B1 (en) * 2011-08-01 2018-10-31 Monash University Method and formulation for inhalation
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same
FR3035826B1 (fr) * 2015-05-07 2018-11-16 Saint-Gobain Glass France Vitrage de vehicule comprenant une platine pour la fixation de plusieurs accessoires, platine et procede de fixation.
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CN105770862B (zh) * 2016-04-22 2022-01-11 北京三元基因药业股份有限公司 干扰素的干粉吸入剂
EP3478265A1 (en) * 2016-06-30 2019-05-08 Philip Morris Products S.a.s. Nicotine particles

Also Published As

Publication number Publication date
IL268458A (en) 2019-09-26
MX2019010263A (es) 2019-10-09
RU2770039C2 (ru) 2022-04-14
RU2019128062A3 (ru) 2021-05-21
CN110300588A (zh) 2019-10-01
JP2020510002A (ja) 2020-04-02
KR20190126772A (ko) 2019-11-12
EP3592352A1 (en) 2020-01-15
WO2018163085A1 (en) 2018-09-13
CA3048677A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
RU2019128062A (ru) Вдыхаемые составы на основе никотина и способы их получения и применения
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
JP2018528966A5 (ru)
RU2018113460A (ru) Вдыхаемые никотиновые композиции и способы их получения и применения
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
JP2016534153A5 (ru)
HUP0300593A2 (hu) Kemény pelletként kialakított gyógyászati készítmény száraz porral mżködż inhalátorhoz
EA201390049A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
GB0425758D0 (en) Preparation of pharmaceutical compositions
RU2018145313A (ru) Никотиносодержащие частицы и композиции
JP2020527377A5 (ru)
JP2013545748A5 (ru)
JP2019519542A5 (ru)
RU2018126867A (ru) Капсула с частицами никотина
JP2013543499A5 (ru)
JP2019524061A5 (ru)
RU2018144108A (ru) Никотиносодержащие частицы
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
EA201590734A1 (ru) Вдыхаемые лекарственные средства
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
EA201591871A1 (ru) Фармацевтическая композиция, содержащая будесонид и формотерол
EA026665B1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
WO2008066810A3 (en) Pleasant tasting dry powder compositions suitable for pulmonary delivery
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone